Human PLC‑ beta3 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF4716
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot
Cited:
Immunoprecipitation, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
E. coli-derived recombinant human PLC-beta 3
Lys27-Leu246
Accession # Q01970
Lys27-Leu246
Accession # Q01970
Specificity
Detects human PLC-beta 3 in Western blots. Does not detect recombinant human (rh) PLC-beta 1, rhPLC-beta 2, or rhPLC-beta 4 in Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human PLC‑ beta3 Antibody
Detection of Human PLC‑ beta3 by Western Blot.
Western blot shows recombinant human PLC-beta 1, PLC-beta 2, PLC-beta 3, PLC-beta 4 (5 ng/lane). PVDF mem-brane was probed with 1 µg/mL Sheep Anti-Human PLC-beta 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4716) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band for PLC-beta 3 was detected at approx-imately 29 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Detection of Human PLC‑ beta3 by Western Blot.
Western blot shows lysates of DU145 human prostate carcinoma cell line, HEK293 human embryonic kidney cell line, and HeLa human cervical epithelial carcinoma cell line. PVDF membrane was probed with 1 µg/mL Sheep Anti-Human PLC-beta 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4716) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band for PLC-beta 3 was detected at approximately 150 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Applications for Human PLC‑ beta3 Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: DU145 human prostate carcinoma cell line, HEK293 human embryonic kidney cell line, and HeLa human cervical epithelial carcinoma cell line
Sample: DU145 human prostate carcinoma cell line, HEK293 human embryonic kidney cell line, and HeLa human cervical epithelial carcinoma cell line
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: PLC-beta 3
The Phospholipase C family consists of 13 isozymes within six subfamilies, PLC-delta, -beta, -gamma, -epsilon, -zeta, and -eta. PLC-beta 3 (Phospholipase C beta-3) is a G-protein dependent phosphodiesterase that catalyzes the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (IP2), an essential step in the intracellular transduction of many extracellular signals. The PLC-beta subfamily consists of 4 isozymes, beta1‑4, which differ in their tissue distribution and their ability to be activated by G proteins. PLC-beta 1 and PLC-beta 3 are more widely expressed, whereas PLC-beta 2 is resticted to hematopoietic cells and PLC-beta 4 is limited to certain neuronal cells and the retina.
Long Name
Phospholipase C beta 3
Alternate Names
PLCB3, PLCbeta 3
Gene Symbol
PLCB3
UniProt
Additional PLC-beta 3 Products
Product Documents for Human PLC‑ beta3 Antibody
Product Specific Notices for Human PLC‑ beta3 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...